Product Information
MYFEMBREE 40 MG-1 MG-0.5 MG TB is a brand product labeled by Sumitomo Pharma America, Inc., priced at $45.2514 per EA under NDC 72974041501. Its NADAC has been published 207 times since Oct 19, 2022.
FDA first approved this application on May 26, 2021.
MYFEMBREE 40 MG-1 MG-0.5 MG TB
relugolix, estradiol hemihydrate, and norethindrone acetateStrength
1; .5; 40 mg/1; mg/1; mg/1
Manufacturer
Sumitomo Pharma America, Inc.NDC
72974041501
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ESTRADIOL HEMIHYDRATE; NORETHINDRONE ACETATE; RELUGOLIXApproval Type
New Drug (NDA)
FDA Application
NDA214846FDA Approved
5/26/2021
On Market Since
5/26/2021
Pharmacological Classes
Price Statistics
The NADAC for MYFEMBREE 40 MG-1 MG-0.5 MG TB has been published 207 times since Oct 19, 2022, and over the history we have for it it has risen 26.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $45.2514 per EA |
|---|---|
| All-time high | $45.3620 (May 13, 2026) |
| All-time low | $35.6728 (Oct 19, 2022) |
| 52-week high | $45.3620 |
| 52-week low | $42.7888 |
| Median price | $40.1348 |
| Average price | $40.8461 |
| Largest weekly change | +7.5% (Jan 10, 2024) |
| Weeks tracked | 207 |
| Tracking since | Oct 19, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the relugolix, estradiol hemihydrate, and norethindrone acetate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sumitomo Pharma America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
relugolix, estradiol hemihydrate, and norethindrone acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MYFEMBREE 40 MG-1 MG-0.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for MYFEMBREE 40 MG-1 MG-0.5 MG TB, manufactured by Sumitomo Pharma America, Inc., is $45.2514 per EA (NDC 72974041501), effective Sep 30, 2026.
How has the price of MYFEMBREE 40 MG-1 MG-0.5 MG TB changed over time?
Over the history we have for it, the NADAC for MYFEMBREE 40 MG-1 MG-0.5 MG TB has risen 26.9%. It has been tracked across 207 weekly CMS publications since Oct 19, 2022.
What are the highest and lowest recorded NADAC prices for MYFEMBREE 40 MG-1 MG-0.5 MG TB?
Since Oct 19, 2022, the NADAC for MYFEMBREE 40 MG-1 MG-0.5 MG TB has ranged from a low of $35.6728 (Oct 19, 2022) to a high of $45.3620 (May 13, 2026), with a median of $40.1348 per EA.
Are there cheaper alternatives to MYFEMBREE 40 MG-1 MG-0.5 MG TB?
No other NADAC-published product currently shares the active ingredient and strength of MYFEMBREE 40 MG-1 MG-0.5 MG TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MYFEMBREE 40 MG-1 MG-0.5 MG TB?
MYFEMBREE 40 MG-1 MG-0.5 MG TB (NDC 72974041501) is labeled by Sumitomo Pharma America, Inc., and CMS classifies it as a brand product.